BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pennisi G, Celsa C, Giammanco A, Spatola F, Petta S. The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives. Int J Mol Sci 2019;20:E5613. [PMID: 31717576 DOI: 10.3390/ijms20225613] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 Li T, Lin X, Shen B, Zhang W, Liu Y, Liu H, Wang Y, Zheng L, Zhi F. Akkermansia muciniphila suppressing nonalcoholic steatohepatitis associated tumorigenesis through CXCR6(+) natural killer T cells. Front Immunol 2022;13:1047570. [PMID: 36531991 DOI: 10.3389/fimmu.2022.1047570] [Reference Citation Analysis]
2 Han J, Wang B, Liu W, Wang S, Chen R, Chen M, Fu Z. Declining disease burden of HCC in the United States, 1992-2017: A population-based analysis. Hepatology 2022;76:576-88. [PMID: 35073427 DOI: 10.1002/hep.32355] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
3 Khan A, Zhang X. Function of the Long Noncoding RNAs in Hepatocellular Carcinoma: Classification, Molecular Mechanisms, and Significant Therapeutic Potentials. Bioengineering 2022;9:406. [DOI: 10.3390/bioengineering9080406] [Reference Citation Analysis]
4 Piras IS, Raju A, Don J, Schork NJ, Gerhard GS, Distefano JK. Hepatic PEMT Expression Decreases with Increasing NAFLD Severity. IJMS 2022;23:9296. [DOI: 10.3390/ijms23169296] [Reference Citation Analysis]
5 Aljabban J, Rohr M, Syed S, Khorfan K, Borkowski V, Aljabban H, Segal M, Mukhtar M, Mohammed M, Panahiazar M, Hadley D, Spengler R, Spengler E. Transcriptome changes in stages of non-alcoholic fatty liver disease. World J Hepatol 2022;14:1382-97. [PMID: 36158924 DOI: 10.4254/wjh.v14.i7.1382] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Ahmad MI, Khan MU, Kodali S, Shetty A, Bell SM, Victor D. Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges. JHC 2022;Volume 9:477-96. [DOI: 10.2147/jhc.s344559] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 D'silva M, Cho JY, Han H, Yoon Y, Lee HW, Lee JS, Lee B, Kim M. Long-term surgical outcomes of Non alcoholic fatty liver disease associated hepatocellular carcinoma. Surgical Oncology 2022;41:101730. [DOI: 10.1016/j.suronc.2022.101730] [Reference Citation Analysis]
8 Ballerini P, Contursi A, Bruno A, Mucci M, Tacconelli S, Patrignani P. Inflammation and Cancer: From the Development of Personalized Indicators to Novel Therapeutic Strategies. Front Pharmacol 2022;13:838079. [DOI: 10.3389/fphar.2022.838079] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
9 Pennisi G, Enea M, Romero-Gomez M, Viganò M, Bugianesi E, Wong VW, Fracanzani AL, Sebastiani G, Boursier J, Berzigotti A, Eslam M, Ampuero J, Benmassaoud A, La Mantia C, Mendoza YP, George J, Craxì A, Camma' C, de Ledinghen V, Petta S. Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis. Aliment Pharmacol Ther 2022;55:604-15. [PMID: 34988994 DOI: 10.1111/apt.16763] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
10 Chrysavgis L, Giannakodimos I, Diamantopoulou P, Cholongitas E. Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link. World J Gastroenterol 2022;28:310-31. [PMID: 35110952 DOI: 10.3748/wjg.v28.i3.310] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
11 Xue W, Zhang L, Liu C, Gao Y, Li S, Huai Z, Dai J, Wang Y. Research progress on the relationship between TM6SF2 rs58542926 polymorphism and non-alcoholic fatty liver disease. Expert Review of Gastroenterology & Hepatology. [DOI: 10.1080/17474124.2022.2032661] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Hanif H, Ali MJ, Susheela AT, Khan IW, Luna-Cuadros MA, Khan MM, Lau DTY. Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma. World J Gastroenterol 2022; 28(2): 216-229 [DOI: 10.3748/wjg.v28.i2.216] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
13 Hanashiro K, Motomura J, Sunagawa M. Association Between Liver Steatosis and Single Nucleotide Polymorphisms in the <i>PNPLA3</i> Gene in the Northern Part of Okinawa, Japan. J J R M 2022;71:309-320. [DOI: 10.2185/jjrm.71.309] [Reference Citation Analysis]
14 Ishida N, Yamada H, Hirose M. Euphausia pacifica (North Pacific Krill): Review of Chemical Features and Potential Benefits of 8-HEPE against Metabolic Syndrome, Dyslipidemia, NAFLD, and Atherosclerosis. Nutrients 2021;13:3765. [PMID: 34836021 DOI: 10.3390/nu13113765] [Reference Citation Analysis]
15 Ziolkowska S, Binienda A, Jabłkowski M, Szemraj J, Czarny P. The Interplay between Insulin Resistance, Inflammation, Oxidative Stress, Base Excision Repair and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:11128. [PMID: 34681787 DOI: 10.3390/ijms222011128] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
16 Chen X, Ma H, Gao Y, Jin Y, Ning W, Hou Y, Su J. Long non-coding RNA AC012668 suppresses non-alcoholic fatty liver disease by competing for microRNA miR-380-5p with lipoprotein-related protein LRP2. Bioengineered 2021;12:6738-47. [PMID: 34511037 DOI: 10.1080/21655979.2021.1960463] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
17 Peng XF, Huang SF, Chen LJ, Xu L, Ye WC. Targeting epigenetics and lncRNAs in liver disease: From mechanisms to therapeutics. Pharmacol Res 2021;172:105846. [PMID: 34438063 DOI: 10.1016/j.phrs.2021.105846] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
18 Johnson ND, Wu X, Still CD, Chu X, Petrick AT, Gerhard GS, Conneely KN, DiStefano JK. Differential DNA methylation and changing cell-type proportions as fibrotic stage progresses in NAFLD. Clin Epigenetics 2021;13:152. [PMID: 34353365 DOI: 10.1186/s13148-021-01129-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
19 Liu G, Cui Z, Gao X, Liu H, Wang L, Gong J, Wang A, Zhang J, Ma Q, Huang Y, Piao G, Yuan H. Corosolic acid ameliorates non-alcoholic steatohepatitis induced by high-fat diet and carbon tetrachloride by regulating TGF-β1/Smad2, NF-κB, and AMPK signaling pathways. Phytother Res 2021. [PMID: 34213784 DOI: 10.1002/ptr.7195] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
20 Koulouris A, Tsagkaris C, Spyrou V, Pappa E, Troullinou A, Nikolaou M. Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options. J Hepatocell Carcinoma 2021;8:387-401. [PMID: 34012929 DOI: 10.2147/JHC.S300182] [Cited by in Crossref: 27] [Cited by in F6Publishing: 34] [Article Influence: 13.5] [Reference Citation Analysis]
21 Coman LI, Coman OA, Bădărău IA, Păunescu H, Ciocîrlan M. Association between Liver Cirrhosis and Diabetes Mellitus: A Review on Hepatic Outcomes. J Clin Med 2021;10:E262. [PMID: 33445629 DOI: 10.3390/jcm10020262] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
22 Dogra N, Mishra S, Mani RJ, Aeri V, Katare DP. Pharmacodynamic biomarker for Hepatocellular carcinoma C: Model-based evaluation for pharmacokinetic–pharmacodynamic responses of drug. Translational Biotechnology 2021. [DOI: 10.1016/b978-0-12-821972-0.00007-1] [Reference Citation Analysis]
23 Risi R, Tuccinardi D, Mariani S, Lubrano C, Manfrini S, Donini LM, Watanabe M. Liver disease in obesity and underweight: the two sides of the coin. A narrative review. Eat Weight Disord 2020. [PMID: 33150534 DOI: 10.1007/s40519-020-01060-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
24 Yatsuji S, Kotera Y, Kogiso T, Saito S, Omori A, Sagawa T, Taniai M, Shimizu K, Yamamoto M, Nakano M, Tokushige K. A case of hemorrhage of hepatocellular carcinoma resembling a hepatic cyst arising from non-cirrhotic steatohepatitis. Clin J Gastroenterol 2021;14:218-23. [PMID: 32979153 DOI: 10.1007/s12328-020-01251-z] [Reference Citation Analysis]
25 Galati G, Massimo Vainieri AF, Maria Fulgenzi CA, Di Donato S, Silletta M, Gallo P, Onorato A, Vespasiani-Gentilucci U, Picardi A. Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis. Curr Drug Metab 2020;21:866-84. [PMID: 32957880 DOI: 10.2174/1389200221999200918141239] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
26 Plaz Torres MC, Bodini G, Furnari M, Marabotto E, Zentilin P, Strazzabosco M, Giannini EG. Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? Cancers (Basel). 2020;12. [PMID: 32486355 DOI: 10.3390/cancers12061422] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
27 Kim YA, Park KK, Lee SJ. LncRNAs Act as a Link between Chronic Liver Disease and Hepatocellular Carcinoma. Int J Mol Sci. 2020;21:2883. [PMID: 32326098 DOI: 10.3390/ijms21082883] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]